Social media

We’re heading to #ISPOREurope in Glasgow (Nov 9–12)! Visit ICON at Booth 824 to explore how we advance HEOR, RWE, and market access strategies for better patient outcomes. https://ow.ly/xEsm50XfmbV #ISPOREurope #HEOR #...

ICON reports third quarter 2025 results. Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025. Net business wins in the quarter of $2,086 million, representing an increase of 1....

USP compounding may be fast — but is it costing you quality, compliance, and insight? Join our webinar to learn why GMP is the smarter choice for early phase trials. During this session we will discuss: • The differences...

USP compounding may be fast — but is it costing you quality, compliance, and insight? Join our webinar to learn why GMP is the smarter choice for early phase trials. During this session we will discuss: • The differences...

Join ICON at #CPHIFrankfurt, taking place from 28 to 30 October at Messe Frankfurt to discover how our Accelerated Pharmaceutical Solutions are built to meet the demands of a fast-moving industry—combining global reach, ...

Join ICON at #CPHIFrankfurt, taking place from 28 to 30 October at Messe Frankfurt to discover how our Accelerated Pharmaceutical Solutions are built to meet the demands of a fast-moving industry—combining global reach, ...

ICON is proud to sponsor the World Drug Safety Congress, 4–6 November in Boston, MA. As a global leader in pharmacovigilance, ICON partners with biopharma and medical device companies of all sizes to strengthen patient ...

ICON is proud to sponsor the World Drug Safety Congress, 4–6 November in Boston, MA. As a global leader in pharmacovigilance, ICON partners with biopharma and medical device companies of all sizes to strengthen patient ...

Are you going to CPHI? If so come along to our VIP in-person event on Tuesday 28th October where our panel of industry experts will discuss the challenges around accelerating timelines and reducing costs in early clinica...

Are you going to CPHI? If so come along to our VIP in-person event on Tuesday 28th October where our panel of industry experts will discuss the challenges around accelerating timelines and reducing costs in early clinica...

By integrating drug substance, formulation development, real-time manufacturing, and clinical testing, we streamline the entire process—cutting up to 12+ months in development time and significantly reducing costs. Del...

By integrating drug substance, formulation development, real-time manufacturing, and clinical testing, we streamline the entire process—cutting up to 12+ months in development time and significantly reducing costs. Del...